Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sour...

Full description

Bibliographic Details
Main Authors: Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Pharmacology Research & Perspectives
Subjects:
atezolizumab
biomarkers
clinical pharmacology
mutation
pharmacokinetics
tumor
Online Access:https://doi.org/10.1002/prp2.685

Internet

https://doi.org/10.1002/prp2.685

Similar Items